Hemispherx (AMEX:HEB) Ampligen Combats H5N1

With the majority of the focus being placed on on the current pending FDA approval regarding (AMEX:HEB) Hemispherx’s Ampligen, StocksHaven Investments would like to shift the focus on the drug’s ability to help treat the potential outbreak of H5N1 (subtype of the Influenza A virus).

Overview of H5N1

H5N1 - also called “Influenza A (H5N1) virus” – is an influenza A virus subtype that occurs mainly in birds, is highly contagious among birds, and can be deadly to them. H5N1 virus does not usually infect people, however recently the infections with these viruses have began to occur in humans.

To evaluate the adjuvant effect of Ampligen, the protective effect of intranasal administration of vaccine and Ampligen adjuvant against homologous and teterologous H5N1 influenza virus challenge was examined.

The full special report appears today at http://www.stockshaven.com/hemispherx-ampligen-combats-h5n1/

Disclosure: Long-Term Position

###

About StocksHaven Investments

StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, discussion forum, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit www.StocksHaven.com

###

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

Michael Vlaicu

Founder, Lead Investment Analyst

StocksHaven Investments

Contact via E-mail